SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Madam C. J. Walker Synthetic CCD

PatientSarah Walker
Date of birth1976-12-23
IdentifiersMRN HR-ET019-SYN; SSN (made up) 000-19-7062
Document date2026-11-01
AuthorHarriet Okonjo-Bell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing care for high blood pressure found at a workplace screening, morning headaches and protein in the urine at last year's executive physical, in a company founder who travels most weeks. Concerns: She wants to keep building her company and keep traveling to her agents, and does not want to be told to slow down; She is worried that her kidneys could fail and wants to know plainly what the numbers mean; She wants a plan that works on the road: medicines, readings, food and tests. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Losartan 50 mg oral tablet, one tablet each morningOne tablet each morning, at the same home time when travelingOral route2026-02-23 to 2026-03-09completedS
Losartan 100 mg oral tablet, one tablet each morningOne tablet each morningOral route2026-03-09activeS
Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgeryOne tablet each morning, with sick-day rulesOral route2026-02-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-02-23activeS
Ondansetron 4 mg orally disintegrating tablet, one tablet on the tongue every 8 hours as needed for nausea, for up to two daysEvery 8 hours as needed for nausea, up to two daysOral route2026-04-13 to 2026-04-15completedS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-04-27activeS

Procedures

ProcedureDatesStatusEvidence
Twelve-lead electrocardiogram2026-02-09 to 2026-02-09completedS
24-hour ambulatory blood pressure monitoring on a day at home, with readings every 20 minutes by day and every 30 minutes by night2026-02-10 to 2026-02-11completedS
Ultrasound of both kidneys and the bladder2026-02-23 to 2026-02-23completedS
Transthoracic echocardiogram2026-03-09 to 2026-03-09completedS
Advance care planning conversation, about 20 minutes2026-06-08 to 2026-06-08completedS
Screening mammogram, both breasts2026-06-22 to 2026-06-22completedS

Immunizations

DateVaccineStatusEvidence
2026-02-09Influenza vaccine, inactivated, this seasoncompletedS
2026-06-08Pneumococcal conjugate vaccine PCV20completedS
2026-06-08Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)completedS
2026-06-08Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
2026-08-17Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1904Hair loss and scalp disease in her thirties, while working as a laundress; resolvedD (CLM-0003)
1916High blood pressure, for which she took a rest cure at Hot Springs, Arkansas, the year before this visit; no treatment recordedD (CLM-0006)

Family History

RelativeConditionAge at deathEvidence
motherDied when she was a young child; cause not recorded in the cited sourceD (CLM-0002)
fatherDied when she was a young child; cause not recorded in the cited sourceD (CLM-0002)

Health Concerns

ConcernStatusEvidence
She wants to keep building her company and keep traveling to her agents, and does not want to be told to slow downactiveS
She is worried that her kidneys could fail and wants to know plainly what the numbers meanactiveS
She wants a plan that works on the road: medicines, readings, food and testsactiveS

Assessment

Most recent measures: Sodium [Moles/volume] in Serum or Plasma 140 on 2026-08-17; Potassium [Moles/volume] in Serum or Plasma 4.8 on 2026-08-17; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 2026-08-17; Creatinine [Mass/volume] in Serum or Plasma 1.3 on 2026-08-17; Glucose [Mass/volume] in Serum or Plasma 88 on 2026-04-13; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 50 on 2026-08-17; Albumin/Creatinine [Mass Ratio] in Urine 128 on 2026-08-17; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-02-09; Cholesterol [Mass/volume] in Serum or Plasma 172 on 2026-04-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 98 on 2026-04-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 48 on 2026-04-27; Triglyceride [Mass/volume] in Serum or Plasma 130 on 2026-04-27; Hemoglobin [Mass/volume] in Blood 12.6 on 2026-08-17; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-02-09; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-08-17; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-02-23; Phosphate [Mass/volume] in Serum or Plasma 3.6 on 2026-02-23; Parathyrin.intact [Mass/volume] in Serum or Plasma 58 on 2026-02-23; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 31 on 2026-02-23; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-04-27; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-06-08; Total score [AUDIT-C] 1 on 2026-06-08 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigatedresolvedconfirmed R80.9S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks.
Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressureactiveconfirmed I12.9S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis.
Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 2021 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6%activeconfirmed N18.31S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease.
Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate)activeconfirmed E78.5S — Synthetic laboratory finding.
Viral gastroenteritis after a sales convention, with mild volume depletion and losartan and empagliflozin held under her sick-day rules; no acute kidney injury; resolvedresolvedconfirmed A08.4S — Synthetic intercurrent illness; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-09Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-02-09Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-02-09Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-02-09Creatinine [Mass/volume] in Serum or Plasma1.22mg/dL0.59-1.04 mg/dLHighS
2026-02-09Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-02-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M54mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS
2026-02-09Albumin/Creatinine [Mass Ratio] in Urine286mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)HighS
2026-02-09Hemoglobin A1c/Hemoglobin.total in Blood5.4%Below 5.7% is normalNormalS
2026-02-09Cholesterol [Mass/volume] in Serum or Plasma250mg/dL<=199 mg/dLHighS
2026-02-09Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation174mg/dLBelow 130 mg/dL; lower on treatment by at least 30%HighS
2026-02-09Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=50 mg/dLLowS
2026-02-09Triglyceride [Mass/volume] in Serum or Plasma150mg/dL<=149 mg/dLHighS
2026-02-09Hemoglobin [Mass/volume] in Blood12.4g/dL12-15.5 g/dLNormalS
2026-02-09Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4.5 mIU/LNormalS
2026-02-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-02-23Albumin/Creatinine [Mass Ratio] in Urine294mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)HighS
2026-02-23Creatinine [Mass/volume] in Serum or Plasma1.21mg/dL0.59-1.04 mg/dLHighS
2026-02-23Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M55mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS
2026-02-23Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
2026-02-23Phosphate [Mass/volume] in Serum or Plasma3.6mg/dL2.5-4.5 mg/dLNormalS
2026-02-23Parathyrin.intact [Mass/volume] in Serum or Plasma58pg/mL15-65 pg/mLNormalS
2026-02-2325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma31ng/mL30-100 ng/mLNormalS
2026-03-09Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-09Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-03-09Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-03-09Creatinine [Mass/volume] in Serum or Plasma1.29mg/dL0.59-1.04 mg/dLHighS
2026-03-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M51mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS
2026-04-13Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-04-13Potassium [Moles/volume] in Serum or Plasma4.9mmol/L3.5-5.1 mmol/LNormalS
2026-04-13Carbon dioxide, total [Moles/volume] in Serum or Plasma21mmol/L22-29 mmol/LLowS
2026-04-13Creatinine [Mass/volume] in Serum or Plasma1.46mg/dL0.59-1.04 mg/dLHighS
2026-04-13Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
2026-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M44mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS
2026-04-27Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-04-27Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-04-27Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-04-27Creatinine [Mass/volume] in Serum or Plasma1.31mg/dL0.59-1.04 mg/dLHighS
2026-04-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M50mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS
2026-04-27Albumin/Creatinine [Mass Ratio] in Urine176mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)HighS
2026-04-27Cholesterol [Mass/volume] in Serum or Plasma172mg/dL<=199 mg/dLNormalS
2026-04-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation98mg/dLBelow 130 mg/dL; lower on treatment by at least 30%NormalS
2026-04-27Cholesterol in HDL [Mass/volume] in Serum or Plasma48mg/dL>=50 mg/dLLowS
2026-04-27Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS
2026-04-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-08-17Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-08-17Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-08-17Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-08-17Creatinine [Mass/volume] in Serum or Plasma1.3mg/dL0.59-1.04 mg/dLHighS
2026-08-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M50mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS
2026-08-17Albumin/Creatinine [Mass Ratio] in Urine128mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)HighS
2026-08-17Hemoglobin [Mass/volume] in Blood12.6g/dL12-15.5 g/dLNormalS
2026-08-17Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-06-08Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-06-08Total score [AUDIT-C]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-02-09Body height163cmS
2026-02-09Body weight79kgS
2026-02-09Body mass index (BMI) [Ratio]29.7kg/m2S
2026-02-09Systolic blood pressure166mm[Hg]S
2026-02-09Diastolic blood pressure102mm[Hg]S
2026-02-09Heart rate82/minS
2026-02-09Respiratory rate16/minS
2026-02-09Body temperature36.7CelS
2026-02-09Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-02-23Body height163cmS
2026-02-23Body weight78.6kgS
2026-02-23Body mass index (BMI) [Ratio]29.6kg/m2S
2026-02-23Systolic blood pressure160mm[Hg]S
2026-02-23Diastolic blood pressure100mm[Hg]S
2026-02-23Heart rate80/minS
2026-02-23Respiratory rate16/minS
2026-02-23Body temperature36.6CelS
2026-02-23Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-03-09Body height163cmS
2026-03-09Body weight78.2kgS
2026-03-09Body mass index (BMI) [Ratio]29.4kg/m2S
2026-03-09Systolic blood pressure148mm[Hg]S
2026-03-09Diastolic blood pressure92mm[Hg]S
2026-03-09Heart rate78/minS
2026-03-09Respiratory rate16/minS
2026-03-09Body temperature36.7CelS
2026-03-09Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-27Body height163cmS
2026-04-27Body weight77.2kgS
2026-04-27Body mass index (BMI) [Ratio]29.1kg/m2S
2026-04-27Systolic blood pressure136mm[Hg]S
2026-04-27Diastolic blood pressure86mm[Hg]S
2026-04-27Heart rate76/minS
2026-04-27Respiratory rate16/minS
2026-04-27Body temperature36.6CelS
2026-04-27Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-17Body height163cmS
2026-08-17Body weight75.8kgS
2026-08-17Body mass index (BMI) [Ratio]28.5kg/m2S
2026-08-17Systolic blood pressure122mm[Hg]S
2026-08-17Diastolic blood pressure76mm[Hg]S
2026-08-17Heart rate72/minS
2026-08-17Respiratory rate16/minS
2026-08-17Body temperature36.7CelS
2026-08-17Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-13Body height163cmS
2026-04-13Body weight76.4kgS
2026-04-13Body mass index (BMI) [Ratio]28.8kg/m2S
2026-04-13Systolic blood pressure112mm[Hg]S
2026-04-13Diastolic blood pressure72mm[Hg]S
2026-04-13Heart rate96/minS
2026-04-13Respiratory rate16/minS
2026-04-13Body temperature37.4CelS
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-06-08Body height163cmS
2026-06-08Body weight76.6kgS
2026-06-08Body mass index (BMI) [Ratio]28.8kg/m2S
2026-06-08Systolic blood pressure126mm[Hg]S
2026-06-08Diastolic blood pressure80mm[Hg]S
2026-06-08Heart rate74/minS
2026-06-08Respiratory rate16/minS
2026-06-08Body temperature36.7CelS
2026-06-08Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-02-09Establishing care for high blood pressure found at a workplace screening, morning headaches and protein in the urine at last year's executive physical, in a company founder who travels most weeksfinishedS
2026-02-23Two-week review of the 24-hour ambulatory blood pressure and the repeat kidney tests, with a kidney ultrasound and a nephrology consultationfinishedS
2026-03-09Two-week check of potassium and creatinine after starting losartan and empagliflozin, home readings, and the echocardiogramfinishedS
2026-04-27Eleven-week review: home readings on maximum losartan, urine albumin, kidney function after a recent gastroenteritis, lipids on atorvastatinfinishedS
2026-08-17Six-month review: blood pressure at goal, urine albumin, kidney function, hemoglobin, mood, and the travel season aheadfinishedS
2026-04-13Same-day sick visit for viral gastroenteritis with sick-day rulesfinishedS
2026-06-08Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Nephrology consultation at the two-week visit for albuminuria and a reduced eGFR found at 49: the likely cause, whether more tests or a biopsy are needed, kidney-protective treatment, APOL1 testing, and monitoring that fits her travelcompletedGL-KDIGO-CKD-2024, GL-CMID-2026S
Confirm the diagnosis outside the office: 24-hour ambulatory monitoring on a day at home, and a validated upper-arm home monitor with a correctly sized cuff that travels with her, two readings morning and evening for seven days, travel days included; recheck in two weekscompletedGL-AHA-HTN-2025, GL-CMID-2026S
Kidney evaluation: repeat urine albumin and creatinine at two weeks, compared with last year's results to establish chronicity; urinalysis; kidney ultrasound; calcium, phosphate, parathyroid hormone and 25-hydroxyvitamin D at baseline; every eGFR reported by the race-free CKD-EPI 2021 equation; no ibuprofen or naproxencompletedGL-KDIGO-CKD-2024, GL-NKF-ASN-2021, GL-CKDEPI-2021, GL-CMID-2026S
Heart and vascular risk: ECG at intake and an echocardiogram for the left ventricular hypertrophy it shows; a fundus examination; TSH and A1c at diagnosis; lipid panel and 10-year ASCVD risk by the Pooled Cohort EquationscompletedGL-AHA-HTN-2025, GL-ACC-CHOL-2018, GL-CMID-2026S
Food: sodium under 2 g a day built on what she eats, not a new diet: a salt-free seasoning blend for the dishes she cooks on Sundays, smoked turkey in small amounts in place of salt pork, ordering strategies for banquets and restaurants, water instead of a third coffee on travel days; video sessions with a registered dietitian between trips; no potassium-based salt substitutes until her kidney tests and any new medicines are settledcompletedGL-AHA-HTN-2025, GL-KDIGO-CKD-2024S
Work and rest on her terms: she sets her schedule; the risks of uncontrolled blood pressure and kidney disease are stated plainly and any medicines are chosen to do the work, timed to her home clock across time zones, with a written sick-day card for her bag; a protected sleep window on travel nights and walking during layovers; video visits between trips and laboratory checks on her days at homecompletedGL-AHA-HTN-2025, GL-KDIGO-CKD-2024S
Mood and stress: PHQ-9 at intake and yearlycompletedGL-USPSTF-DEP-2023, GL-CMID-2026S
Vaccines: influenza today; pneumococcal, hepatitis B and Tdap needs reviewed at the preventive visit; influenza and COVID-19 each autumncompletedGL-CDC-IMZ-2026S
Gastroenteritis: oral rehydration, ondansetron as needed, losartan and empagliflozin held until she has eaten and drunk normally for 24 hours, then restarted; a metabolic panel within a weekcompletedGL-KDIGO-CKD-2024S
As the nephrologist advised: losartan 50 mg, increased to 100 mg at two weeks if potassium and creatinine allow; empagliflozin 10 mg daily; sick-day rules for both; potassium and creatinine two to four weeks after each start or increase, accepting a creatinine rise of up to 30%; urine albumin at about three months, then every six months; blood pressure goal below 130/80, lower toward a systolic of 120 if well tolerated, with amlodipine as the next medicinecompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-AHA-HTN-2025, GL-CMID-2026S
Atorvastatin 20 mg daily, chosen with her after reviewing her 10-year ASCVD risk of 7.9% with CKD as a risk enhancer; lipid panel and ALT at four to twelve weekscompletedGL-ACC-CHOL-2018, GL-KDIGO-CKD-2024, GL-CMID-2026S
Amlodipine 5 mg added for home readings above goal on losartan 100 mg; every laboratory check booked on a home day before her trips are scheduled, by her office, after two missed checkscompletedGL-AHA-HTN-2025, GL-KDIGO-CKD-2024, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Blood pressure below 130/80 mmHg in the clinic and at home within six months, lower toward a systolic of 120 if well tolerated2026-08-17completed122/76 in the clinic; home average 123/77 on losartan 100 mg and amlodipine 5 mgS
Urine albumin-to-creatinine ratio lower by at least 30% within six months2026-08-17completed286 to 294 mg/g at baseline; 128 mg/g at six months, 56% lowerS
Kidney function stable, without a fall in eGFR of more than 30% after starting treatment2026-08-17completedeGFR 54 to 55 at baseline; 50 to 51 on treatment, a dip of under 10%S
Sodium under 2 g a day using foods she likes, at home and on the road2026-08-17activeSalt-free seasoning at home and ordering strategies on the road; restaurant meals still the hardest partS
LDL cholesterol lower by at least 30%2026-04-27completed174 to 98 mg/dL on atorvastatin 20 mg, 44% lowerS
Care that fits her work: every check scheduled around her travel, by her choice2026-08-17completedLaboratory checks booked before trips are planned after two missed checks; video visits between tripsS

Functional Status

Mental Status